Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 6
Submit an article Journal homepage
206
Views
19
CrossRef citations to date
0
Altmetric
Review

The cost offsets and cost–effectiveness associated with pegylated drugs: a review of the literature

Russell Becker Russell Becker Consulting, Chicago, IL, USA. [email protected]
,
Carole Dembek Avalere Health, Washington, DC, USA
,
Leigh Ann White Biogen Idec, Weston, MA, USA
&
Louis P Garrison VeriTech Corporation, University of Washington, Seattle, WA, USA
Pages 775-793 | Published online: 09 Jan 2014

References

  • Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252(11), 3578–3581 (1977).
  • Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin. Drug Deliv. 6(1), 1–16 (2009).
  • Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann. Pharmacother. 34(7–8), 915–923 (2000).
  • Motzer R, Thompson J, Gurney H et al. Phase II trial of branched PEG (40 kDa) interferon α-2a for patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 20, 180a (2001).
  • Yowell SL, Blackwell S. Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat. Rev. 28(Suppl. A), 3–6 (2002).
  • Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat. Rev. 28(Suppl. A), 13–16 (2002).
  • Peters BG, Goeckner BJ, Ponzillo JJ, Velasquez WS, Wilson AL. PEGaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. Formulary 30(7), 388–393 (1995).
  • Vanni T, Fonseca BA, Polanczyk CA. Cost–effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi’s sarcoma in Brazil. HIV Clin. Trials 7(4), 194–202 (2006).
  • Bennett CL, Golub RM, Stinson TJ et al. Cost–effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi’s sarcoma. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18(5), 460–465 (1998).
  • Hjortsberg C, Persson U, Lidbrink E, Bennett C. Cost–effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi’s sarcoma. Acta Oncol. 38(8), 1063–1067 (1999).
  • Porter CA, Rifkin RM. Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma. Clin. Lymphoma Myeloma 7(Suppl. 4), S150–S155 (2007).
  • Liu Z, Doan QV, Malin J, Leonard R. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl. Health Econ. Health Policy 7(3), 193–205 (2009).
  • Lyman GH, Lalla A, Barron RL, Dubois RW. Cost–effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin. Ther. 31(5), 1092–1104 (2009).
  • Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 11(2), 172–179 (2008).
  • Sullivan SD, Jensen DM, Bernstein DE et al. Cost–effectiveness of combination peginterferon α-2a and ribavirin compared with interferon α-2b and ribavirin in patients with chronic hepatitis C. Am. J. Gastroenterol. 99(8), 1490–1496 (2004).
  • Annemans L, Warie H, Nechelput M, Peraux B. A health economic model to assess the long term effects and cost–effectiveness of PEG IFN α-2a in hepatitis C virus infected patients. Acta Gastroenterol. Belg. 67(1), 1–8 (2004).
  • Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and PEG interferon α-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess. 10(iii–iv, xi–xiv), 1–183 (2006).
  • Carrera F, Lok CE, de Francisco A et al.; PATRONUS Investigators. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin β versus darbepoetin α administered monthly: a randomized comparative trial. Nephrol. Dial. Transplant. 25(12), 4009–4017 (2010).
  • Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, NY, USA (2005).
  • Neupogen®, package insert. Amgen Inc, Thousand Oaks, CA, USA.
  • Neulasta®, package insert. Amgen Inc, Thousand Oaks, CA, USA.
  • Sehouli J, Goertz A, Steinle T et al. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost–effectiveness analysis for Germany]. Dtsch. Med. Wochenschr. 135(9), 385–389 (2010).
  • Samaras P, Blickenstorfer M, Siciliano RD et al. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Ann. Hematol. 90(1), 89–94 (2011).
  • Heaney ML, Toy EL, Vekeman F et al. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer 115(20), 4839–4848 (2009).
  • Lago S, Nasciben V, Saggia M. Cost-minimization analysis of once-per-cycle fixed-dose administration of PEGfilgrastim versus dail filgrastrim for the prophylaxis of chemotherapy-induced febrile neutropenia in Brazil. Presented at: ISPOR Tenth Annual European Congress. Dublin, Ireland, 20–23 October 2007.
  • Mayordomo J, Pousa A, Arocho R, Doan QV, Dubois RW, Liu Z. Primary prophylaxis with PEGfilgrastim is cost-saving compared with filgrastim for breast cancer in Spain. Presented at: ISPOR Ninth Annual European Congress. Copenhagen, Denmark, 28–31 October 2006.
  • Suczs T, Standaert B, Lu Z. Analysis on cost difference between daily filgrastim and one per cycle pegfilgrastim for prophylaxis against chemotherapy-induced neutropenia in France and Germany. Presented at: ISPOR Sixth Annual European Congress. Barcelona, Spain, 9–11 November 2003.
  • Bogillot O, Dubois R, Doan Q, Liu Z, Heissel A, Di Palma M. Primary prophylaxis with PEGfilgrastim is cost-saving compared with filgrastim for breast cancer in France. Presented at: ISPOR Ninth Annual European Congress. Copenhagen, Denmark, 28–31 October 2006.
  • Booth P, Dubois R, Doan Q, Liu Z. Cost utility analysis of primary prophylaxis with pegfilgrastim versus filgrastim for breast cancer in the UK. Presented at: ISPOR Ninth Annual European Congress. Copenhagen, Denmark, 28–31 October 2006.
  • Perrier L, Lefranc A, Quittet P et al. Cost–effectivenss of pegfligrastim versus filgrastim after high-dose chemctherapy and autologous stem cell transplantation in patients with lymphoma nad myeloma. Presented at: ISPOR Fourteenth Annual European Congress, Madrid, Spain, 5–8 November 2011.
  • Chiroli S, Health Ciceri F, Atchison C, Malin J, Doan Q. Primary prophylaxis against febrile neutropenia with PEGfilgrastim is cost-effective compared with filgrastim in non-Hodgkin’s lymphoma patients receiving chop-21 in Italy. Presented at: ISPOR Tenth Annual European Congress. Dublin, Ireland, 20–23 October 2007.
  • Taylor D, Ozer-Deniz S, Hill G, Skornicki M, Danel A, Erika K. Cost–effectiveness of primary prophylaxis with PEGfilgrastim versus filgrastim for reducing incidence of febrile neutropenia in non-Hodgkin lymphoma and stage II breast cancer patients in Germany. Presented at: ISPOR 13th Annual European Conference. Prague, Czech Republic, 6–9 November 2010.
  • Chiroli S, Dubois R, Doan Q et al. Cost effectiveness of primary prophylaxis with pegfilgrastim or filgrastim in the medical treatment of breast cancer in Italy. Presented at: ISPOR Ninth Annual European Congress. Copenhagen, Denmark, 28–31 October 2006.
  • Danova M, Chiroli S, Rosti G, Doan QV. Cost–effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori 95(2), 219–226 (2009).
  • Lyman G, Lalla A, Barron R, Dubois RW. Cost–effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin’s lymphoma receiving CHOP-21 in United States. Curr. Med. Res. Opin. 25(2), 401–411 (2009).
  • Arocho R, Atchison C, Malin J. Primary prophylaxis against febrile neutropenia with PEGfilgrastim is cost-effective compared with filgrastim in non-Hodgkin’s lymphoma patients receiving CHOP-21 in Spain. Presented at: ISPOR Tenth Annual European Congress. Dublin, Ireland, 20–23 October 2007.
  • Doxil®, package insert. Janssen Biotech, Horsham, PA, USA.
  • Pegasys®, package insert. Genentech, South San Francisco, CA, USA.
  • PegInteron®, package insert. Merck, Whitehouse Station, NJ, USA.
  • Hornberger J, Torriani FJ, Dieterich DT et al. Cost–effectiveness of peginterferon α-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J. Clin. Virol. 36(4), 283–291 (2006).
  • Fonseca MC, Araújo GT, Araújo DV. Cost effectiveness of peginterferon α-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil. Braz. J. Infect. Dis. 13(3), 191–199 (2009).
  • Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost–effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 290(2), 228–237 (2003).
  • Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. PEG interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol. Assess. 8(iii–iv), 1–125 (2004).
  • Orlewska E, Juszczyk J. The cost–effectiveness analysis of PEGinterferon α-2a and ribavirin versus interferon α-2b and ribavirin in chronic hepatitis C in Poland. Presented at: ISPOR Sixth Annual European Congress. Barcelona, Spain, 9–11 November 2003.
  • Eandi M, Iannazzo S, Pradelli L. Cost–effectiveness of PEGinterferon α-2a (40 kd) for the treatment of chronic hepatitis B in Italy. Presented at: ISPOR Ninth Annual European Congress. Copenhagen, Denmark, 28–31 October 2006.
  • Wright M, Grieve R, Roberts J, Main J, Thomas HC; UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol. Assess. 10(21), 1–113, iii (2006).
  • Mar J, Antonanzas F, Velasco M et al. Cost–effectiveness analysis of PEG interferons combined with ribavirin in the treatment of hepatitis C. Presented at: ISPOR Sixth Annual European Congress. Barcelona, Spain, 9–11 November 2003.
  • Oncaspar®, package insert. Sigma-Tau Pharmaceuticals Inc, Gaithersburg, MD, USA.
  • Kurre HA, Ettinger AG, Veenstra DL et al. A pharmacoeconomic analysis of PEGaspargase versus native Escherichia coli l-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children’s Cancer Group study (CCG-1962). J. Pediatr. Hematol. Oncol. 24(3), 175–181 (2002).
  • Mircera®, package insert. Hoffmann-La Roche Inc, Nutley, NJ, USA.
  • Kawalec P, Kuzma J, Szkultecka-Debek M et al. Cost-minimization analysis: Mircera (methoxypolytheylene glycol-epoetin β) vs. Anranesp (darbepoetin α) in patients with chronic kidney disease (CKD) who are not receiving haemodialysis, in Polish setting. Presented at: ISPOR 12th Annual European Conference. Paris, France, 24–27 October 2009.
  • Garrison LP Jr, Mansley EC, Abbott TA 3rd, Bresnahan BW, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost–effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report–Part II. Value Health 13(1), 8–13 (2010).
  • Mintz C. Biotech Pioneer. Life Sci. Leader (2009).
  • Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin. Emerg. Drugs 14(2), 363–380 (2009).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.